Markets

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

A pen and a calculator.
Credit: Shutterstock photo

In the latest trading session, Gilead Sciences (GILD) closed at $76.29, marking a +0.9% move from the previous day. This change outpaced the S&P 500's 0.44% loss on the day. Elsewhere, the Dow lost 0.53%, while the tech-heavy Nasdaq lost 0.26%.

Coming into today, shares of the HIV and hepatitis C drugmaker had lost 2.93% in the past month. In that same time, the Medical sector gained 5.37%, while the S&P 500 gained 3.59%.

Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be October 25, 2018. In that report, analysts expect GILD to post earnings of $1.62 per share. This would mark a year-over-year decline of 28.63%. Meanwhile, our latest consensus estimate is calling for revenue of $5.38 billion, down 17.31% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of $6.57 per share and revenue of $21.58 billion, which would represent changes of -25.68% and -17.32%, respectively, from the prior year.

Any recent changes to analyst estimates for GILD should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GILD is currently a Zacks Rank #1 (Strong Buy).

Investors should also note GILD's current valuation metrics, including its Forward P/E ratio of 11.51. This represents a discount compared to its industry's average Forward P/E of 29.49.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 38% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More